| pubmed-article:12920390 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0029921 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0473169 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0011570 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0074393 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0262926 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0332119 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C0524893 | lld:lifeskim |
| pubmed-article:12920390 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:12920390 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:12920390 | pubmed:dateCreated | 2003-8-15 | lld:pubmed |
| pubmed-article:12920390 | pubmed:abstractText | While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patients with a history of TRD who responded but later relapsed. Twelve patients with TRD who had not responded to a number of antidepressant trials (n=7), or had responded but subsequently suffered a relapse (n=5), were enrolled in an 8-week, open trial of sertraline. Both a completer analysis (n=6) and an intent-to-treat (ITT) analysis (n=12) were performed to evaluate sertraline response rates. Using a completer analysis, four patients (66.6%) were classified as responders; one (16.7%) as a partial responder and one (16.7%) as a non-responder. An ITT analysis resulted in five (41.7%) patients being classified as responders; one (8.3%) as a partial responder and six (50%) as non-responders. Of the four responders in the completer analysis, three (50%) achieved remission. Of the five responders in the ITT analysis, four (33.3%) achieved remission. Overall, two of seven (28.6%) non-responders and three of five (60.0%) relapsers responded to sertraline. The present results suggest the potential utility of sertraline for patients with TRD, or those with a history of TRD who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of sertraline for such patients. | lld:pubmed |
| pubmed-article:12920390 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920390 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12920390 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920390 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12920390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920390 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12920390 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12920390 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12920390 | pubmed:issn | 0268-1315 | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:NierenbergAnd... | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:PetersenTimot... | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:PapakostasGeo... | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:AlpertJonatha... | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:FavaMaurizioM | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:WorthingtonJo... | lld:pubmed |
| pubmed-article:12920390 | pubmed:author | pubmed-author:RoffiPamela... | lld:pubmed |
| pubmed-article:12920390 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12920390 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:12920390 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12920390 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12920390 | pubmed:pagination | 293-6 | lld:pubmed |
| pubmed-article:12920390 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:meshHeading | pubmed-meshheading:12920390... | lld:pubmed |
| pubmed-article:12920390 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12920390 | pubmed:articleTitle | A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. | lld:pubmed |
| pubmed-article:12920390 | pubmed:affiliation | Depression Clinical and Research program, Department of Psychiatry, Massachusetts General Hospital, 156 Parkman Street, WACC #812, Boston, MA 02114, USA. gpapakostas@partners.org | lld:pubmed |
| pubmed-article:12920390 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12920390 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:12920390 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
